6533b831fe1ef96bd1299b93
RESEARCH PRODUCT
Celecoxib plus carboplatin in heavily pre-treated patients with recurrent ovarian carcinoma: preliminary results of a Phase II study
Gabriella FerrandinaAmelia PagliaM. ColangeloGiovanni ScambiaFrancesco LeggeVanda SalutariDomenica LorussoValerio GallottaAntonia Carla TestaFabio Fulfarosubject
OncologyCancer ResearchPoor prognosisChemotherapymedicine.medical_specialtybusiness.industrymedicine.medical_treatmentPhases of clinical researchmedicine.diseaseCarboplatinchemistry.chemical_compoundOrally activeOncologychemistryInternal medicinemedicineCelecoxibOvarian cancerbusinessRecurrent Ovarian Carcinomamedicine.drugdescription
5060 Background: Cyclooxygenase-2 (COX-2) expression is associated with a poor chance of response to chemotherapy and poor prognosis in ovarian cancer (OC). Celecoxib, an orally active COX-2 inhibi...
year | journal | country | edition | language |
---|---|---|---|---|
2005-06-01 | Journal of Clinical Oncology |